Navigation Links
UGA researchers discover mechanism that explains how cancer enzyme winds up on ends of chromosomes

Human cancer cells divide and conquer. Unless physicians can control that division with surgery, chemotherapy or radiation, the wildly dividing cells will eventually destroy a person's life.

Researchers have known for some time that an enzyme called telomerase is crucial to cancer's progress. Now, for the first time, researchers at the University of Georgia's Franklin College of Arts and Sciences have shown a mechanism that explains how two essential components of human telomerasenormally active only in early prenatal development but turned back on during cancer growthare "recruited" from distinct sites in the cell to the telomere, an area at the end of a chromosome that normally protects it from destruction.

"Telomerase is reactivated in more than 90 percent of human cancers," said Michael Terns, professor of biochemistry and molecular biology and genetics at UGA, "and the fact that telomerase keeps these telomeres growing when it should be inactive is crucial for the proliferation of cancer. That makes telomerase a very promising target for a potential drug to stop cancers from spreading."

The research was just published in the journal Molecular Biology of the Cell. Other authors on the paper were Rebecca Terns, a senior research scientist also in UGA's department of biochemistry and molecular biology (Michael and Rebecca Terns are a husband-wife team); Rebecca Tomlinson, a former doctoral student in the Terns Lab; Eladio Abreu, a current graduate student in the Terns lab; Tania Ziegler, also a former member of the Terns lab, now pursuing an M.D. degree; Hinh Ly of Emory University; and Christopher Counter of Duke University Medical Center. Rebecca and Michael Terns are also members of the University of Georgia Cancer Center.

The two essential components of human telomerase are telomerase RNA and telomerase reverse transcriptase. They are "recruited" to telomeres during what is called the "S phase" (for synthesis) of the cell cycle when DNA replication or synthesis occurs.

"What we have found is that during the remainder of the cell cycle, telomerase RNA is found primarily in rather mysterious and, until recently, little-understood structures called Cajal bodies," said Rebecca Terns. "Though science has known about Cajal [pronounced Ca-HAHL] bodies for more than a hundred years, what we have discovered is that the localization of telomerase RNA to Cajal bodies and telomeres is specific to cancer cells where telomerase is active."

The new research shows for the first time that the trafficking of telomerase RNA to both telomeres and Cajal bodies depends on the presence of telomerase reverse transcriptase.

The Terns lab took advantage of the differences between normal and cancer cells of many kinds to better understand the trafficking of telomerase RNA.

"We examined a variety of factors that differ between normal and cancer cells in order to identify factors that impact human telomerase localization," said Michael Terns. "Our results indicate that human reverse transcriptase is a key determinant in human telomerase trafficking and is essential for the localization of telomerase RNA both to Cajal bodies and telomeres."

While all this jargon-filled science may sound difficult to understand, the discovery could lead to new ways to attack cancers by blocking their ability to grow. While that is years down the road, the new understanding of how this crucial biological action in the human body takes place will at the very least open new avenues of investigation into why and how cancer cells continue to grow and take the human toll they do every day.


Contact: Kim Osborne
University of Georgia

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: